

CURRICULUM VITAE FOR CLEVELAND CLINIC LERNER COLLEGE OF MEDICINE

JUNE 24, 2022

PERSONAL INFORMATION

Name; last, first middle	Zabor, Emily Craig
Credentials; MD, PhD, etc.	MS, DrPH
Institution / Institute	Cleveland Clinic, Lerner Research Institute
Department	Quantitative Health Sciences
Office Address & Mail Code	9500 Euclid Ave, Cleveland, OH 44195, CA6-158
Office Phone	216-445-9419
Office Email	zabore2@ccf.org

EDUCATION & TRAINING

Education

School & City, State / Country	Grinnell College, Grinnell, IA
Degree	BA, Anthropology
Start-End Dates	08/1999 – 05/2003
School & City, State / Country	University of Minnesota, Minneapolis, MN
Degree	MS, Biostatistics
Start-End Dates	08/2008 – 05/2010
School & City, State / Country	Columbia University, New York, NY
Degree	DrPH, Biostatistics
Start-End Dates	01/2013 – 02/2019

PhD Thesis

Title	Statistical Methods for the Study of Etiologic Heterogeneity
Thesis Committee Members	Colin B. Begg, Shuang Wang, Yuanjia Wang, Min Qian, Mary Beth Terry

PROFESSIONAL APPOINTMENTS

Position	Assistant Staff
Institution / Institute	Cleveland Clinic, Lerner Research Institute
Department	Department of Quantitative Health Sciences
Start-End Dates	07/2019 - present
Position	Senior Research Biostatistician
Institution & Institute	Memorial Sloan Kettering Cancer Center
Department	Department of Epidemiology & Biostatistics
City, State / Country	New York, New York, USA
Start-End Dates	04/2018 – 06/2019
Position	Research Biostatistician II
Institution & Institute	Memorial Sloan Kettering Cancer Center
Department	Department of Epidemiology & Biostatistics
City, State / Country	New York, New York, USA

Start-End Dates	08/2015 – 03/2018
Position	Research Biostatistician
Institution & Institute	Memorial Sloan Kettering Cancer Center
Department	Department of Epidemiology & Biostatistics
City, State / Country	New York, New York, USA
Start-End Dates	10/2012 – 07/2015
Position	Assistant Research Biostatistician
Institution & Institute	Memorial Sloan Kettering Cancer Center
Department	Department of Epidemiology & Biostatistics
City, State / Country	New York, New York, USA
Start-End Dates	08/2010 – 09/2012

ACADEMIC APPOINTMENTS

Rank, Department	Assistant Professor of Medicine
Institution & City, State / Country	Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, Ohio, USA
Start-End Dates	03/2020 - present
Rank, Department	Adjunct Professor
Institution & City, State / Country	Hunter College, New York, New York, USA
Start-End Dates	09/2016 - 06/2017

ADDITIONAL CAREER DEVELOPMENT

Research Development

School / Institution	The University of Minnesota, Division of Health Policy & Management
Title / Certificate	Research Assistant
Start-End Dates	2008-2009
School / Institution	National Institutes of Health, Eunice Kennedy Shriver National Institute for Child Health & Human Development
Title / Certificate	Summer Intern in Biomedical Research
Start-End Dates	2009
School / Institution	The University of Minnesota, Coordinating Centers for Biometric Research
Title / Certificate	Research Assistant
Start-End Dates	2009-2010

Editorial Development

School / Institution	American Society of Clinical Oncology
Title / Certificate	Editorial Fellowship, Journal of Clinical Oncology
Start-End Dates	July 1, 2022-June 30, 2023

MEMBERSHIP IN PROFESSIONAL SOCIETIES

Name of Society	American Statistical Association
Role / Title	Member
Start-End Dates	2010-present
Name of Society	Eastern North American Region of the International Biometric Society
Role / Title	Member
Start-End Dates	2011-present

Name of Society American Society of Clinical Oncology
Role / Title Member
Start-End Dates 2015-2019

Name of Society Society for Epidemiologic Research
Role / Title Member
Start-End Dates 2017-2019

Name of Society Eastern North American Region of the International Biometric Society
Role / Title Council for Emerging and New Statisticians Committee Member
Start-End Dates 2019-2021

PROFESSIONAL SERVICES

Editorial Board Membership

Journal 1 Journal of Urology, Editorial Board of Statisticians
Start-End Dates 2018-2020

Journal 2 European Urology, Statistical Associate Editor
Start-End Dates 2019-2021

Journal 3 R Journal, Associate Editor
Start-End Dates 2020-present

Journal 4 Journal of Urology, Chief Statistician
Start-End Dates 2021-present

Manuscript Reviewer

Journal 1 Journal of Urology
Start-End Dates 2013-2017

Journal 2 Journal of Clinical Oncology
Start-End Dates 2017-present

Journal 3 Journal of the American Statistical Association
Start-End Dates 2018-present

Journal 3 R Journal
Start-End Dates 2019-2020

Advisory Groups

Organization R-Ladies, NYC
Title Board Member
Start-End Dates 2016-2019

COMMITTEE SERVICE

Cleveland Clinic

Committee Name / Role CCLCM Clinic Research Block Presentations, Faculty Assessor
Start-End Dates 2019, 2020

Committee Name / Role 2nd Annual Advances in Early Lung Cancer Detection Conference Breakout
Sessions, Statistician Contributor
Start-End Dates 2019

Committee Name / Role	LRI Staff Biostatistician, Search Committee Member
Start-End Dates	2020
Committee Name / Role	CCF Research Day, Clinical Abstract Review Committee Member
Start-End Dates	2020
Committee Name / Role	Taussig Cancer Institute Hematologic Fellows Journal Club, Statistical Mentor
Start-End Dates	2020-present

Memorial Sloan Kettering Cancer Center

Committee Name / Role	R User Group, Member
Start-End Dates	2016-2019
Committee Name / Role	Coding Workshop, Founder & Chair
Start-End Dates	2018-2019

HONORS & AWARDS

Mortar Board Honor Society, Grinnell College, 2002-2003

Ralph A. Leubben Prize for Anthropology, Grinnell College, 2003

Outstanding Teaching Assistant Award, The University of Minnesota, 2009

Travel Awardee, American Statistical Association Section on Statistics in Epidemiology, 2017

TEACHING ACTIVITIES

Curriculum/ Course Development

1. Introduction to Biostatistics, Hunter College, New York , NY
Spent 3 hours/week creating content and 3 hours/week teaching the course, 2016-2017 academic year. Developed the full curriculum including selecting textbooks, creating course content, designing assignments, writing exams. Graded all assignments and exams. Answered student questions and provided feedback.

Invited Lectures

International

1. “Bayesian Basket Trial Design With False Discovery Rate Control.” International Indian Statistical Association Conference, Virtual. 05/2021.
2. “Brief Introduction to Phase II Designs in Oncology.” Seventh International Conference on Statistics for Twenty-first Century, Virtual. 12/2021.
3. “Bayesian Basket Trial Design with False Discovery Rate Control.” 43rd Annual Conference of the International Society for Clinical Biostatistics, Newcastle, United Kingdom. 08/2022.

National

1. “How Long Will I Live? The Statistics Behind Prognosis In Cancer Research.” New York R Conference, New York, NY. 04/2018.
2. “Teaching Survival Analysis To Clinical Collaborators.” R/Medicine Conference, New Haven, CT. 09/2018.

3. "Statistical Methods For The Study Of Etiologic Heterogeneity." NYU School of Medicine Department of Population Health, Division of Biostatistics, New York, NY. 10/2018.
4. "Statistical Methods For The Study Of Etiologic Heterogeneity." Memorial Sloan Kettering Cancer Center Department of Epidemiology & Biostatistics, New York, NY. 12/2018.
5. "Reporting Effect Size And Precision In Clinical Research." American Urological Association Methods in Clinical Urology Research (MCURe) Workshop, Virtual. 07/2021.
6. "Correlating Surrogate Endpoints With Overall Survival At The Individual Patient Level For Precision Oncology." Joint Statistical Meetings, Virtual. 08/2021.
7. "Optimal Sequential Predictive Probability Designs for Early Phase Expansion Cohorts." Eastern North American Region of the International Biometric Society Meetings, Houston, TX. 03/2022.
8. "Estimands, interval censoring, and COVID-19-related disruptions to oncology clinical trials." University of Colorado Biostatistics Seminar Series, Virtual. 04/2022.
9. Title TBD. Dana-Farber Cancer Institute Department of Data Science Frontiers in Biostatistics Seminar Series. 02/2023.
10. Title TBD. DIA Innovative Designs Scientific Working Group KOL Lecture Series. 10/2023.

Regional/Midwest

1. "Validity Of A Method For Identifying Disease Subtypes That Are Etiologically Heterogeneous." Mayo Clinic Department of Health Sciences Research, Rochester, MN. 09/2018.

Local

1. "Statistical Methods For The Study Of Etiologic Heterogeneity." Cleveland Clinic Department of Quantitative Health Sciences, Cleveland, OH. 11/2018.
2. "Creating Presentation-Ready Summary Tables With {gtsummary}." Greater Cleveland R User Group, Cleveland, OH. 09/2020.

Grand Rounds

National

1. "Etiologic Heterogeneity In Cancer." Cleveland Clinic Florida Cancer Grand Rounds, Weston, FL. 01/2020.

Other Presentations

International

1. "Initial Reactions To Tobacco And Risk Of Future Regular Tobacco Use." Poster presentation, Third North American Congress of Epidemiology, Montreal, Canada. 06/2011.
2. "A Review Of Statistical Methods For Evaluating Etiologic Heterogeneity." Oral presentation, Third International Molecular Pathologic Epidemiology Meeting, Boston, MA. 03/2016.
3. "Variable Selection and Its Applications in Biomedical Sciences." Session chair, International Indian Statistical Association Meeting, Virtual. 05/2021.

National

1. "Association Between Periodontal Disease, Bacterial Vaginosis, And Sexual Risk Behaviours." Oral presentation, American Association for Dental Research Meetings, Washington DC. 03/2010.

2. “A Comparison Of Statistical Methods For The Study Of Etiologic Heterogeneity.” Poster presentation, Eastern North American Region of the International Biometric Society, Washington DC. 03/2017.
3. “A Comparison Of Statistical Methods For The Study Of Etiologic Heterogeneity.” Poster presentation, Society for Epidemiologic Research, Seattle, WA. 06/2017.
4. “Dimension Reduction In The Study Of Etiologic Heterogeneity.” Oral presentation, Joint Statistical Meetings, Baltimore, MD. 09/2017.
5. “Validity Of A Method For Identifying Disease Subtypes That Are Etiologically Heterogeneous.” Oral presentation, Eastern North American Region of the International Biometric Society, Atlanta, GA. 03/2018.
6. “Validity Of A Method For Identifying Disease Subtypes That Are Etiologically Heterogeneous.” Oral/poster presentation, Joint Statistical Meetings, Vancouver, Canada. 07/ 2018.
7. “Trial Design with Subpopulation Heterogeneity: What Is the Role of Real-World Evidence?” Session chair, Joint Statistical Meetings, Virtual. 08/2020.
8. “Designing Early Phase Clinical Trials With {ppseq}.” R/Medicine Conference, Virtual. 08/2021.

Teaching Activities

1. Teaching Assistant, Introduction to Biostatistics, 10 hours/week. Graduate students of The University of Minnesota, Minneapolis, MN, 2008-2010.
2. Teaching Assistant, Advanced Topics in Clinical Trials, 10 hours/week. Graduate students of The University of Minnesota, Minneapolis, MN, 2008-2010.
3. Teaching Assistant, Data Science I, 10 hours/week. Graduate students of Columbia University, New York, NY, 2017.
4. “Binary Recursive Partitioning With {rpart} and {rpart.plot}.” Masters Seminar Series, Memorial Sloan Kettering Cancer Center Department of Epidemiology & Biostatistics, New York, NY, 1 hour tutorial, 08/2011.
5. “Conditional Survival.” Masters Seminar Series, Memorial Sloan Kettering Cancer Center Department of Epidemiology & Biostatistics, New York, NY, 1 hour tutorial, 11/2012.
6. “Longitudinal Data Analysis.” Masters Seminar Series, Memorial Sloan Kettering Cancer Center Department of Epidemiology & Biostatistics, New York, NY, 1 hour tutorial, 07/2015.
7. “Demonstration of Utility Functions for R Markdown Reports in Word.” R User Group, Memorial Sloan Kettering Cancer Center Department of Epidemiology & Biostatistics, New York, NY, 1 hour tutorial, 12/2016.
8. “Creating Websites in R.”
R User Group, Memorial Sloan Kettering Cancer Center Department of Epidemiology & Biostatistics, New York, NY, 1 hour tutorial, 01/2018.
R-Ladies NYC Meeting, 1 hour tutorial, 02/2018.
Produced a public-facing website with resulting content at
https://www.emilyzabor.com/tutorials/rmarkdown_websites_tutorial.html.
9. “Survival Analysis in R.” R Presenter Series, Memorial Sloan Kettering Cancer Center Department of Strategy & Innovation, New York, NY, 1 hour tutorial, 08/2018.
10. “Introduction to Survival Analysis,” two 3-hour lectures. Masters-level biostatisticians of Memorial Sloan Kettering Cancer Center Department of Epidemiology & Biostatistics, New York, NY, 03/2019.

Produced a public-facing website with the resulting content at https://www.emilyzabor.com/tutorials/survival_analysis_in_r_tutorial.html. This material has been widely used and shared for training purposes internally, nationally, and internationally. 2 hours/quarter maintaining and updating.

11. Co-Instructor, Biostatistics and Epidemiology, two 2-hour lectures. PhD students of Cleveland Clinic Lerner College of Medicine Molecular Medicine program, 05/2021.
12. Faculty Methodologist, Clinical Research Methods Journal Club, 2 hour session. Cleveland Clinic Lerner Collage of Medicine students, 07/2021.
13. Guest lecturer, Tools course, “Introduction to R and RStudio,” 3 hour lecture. PhD students of Cleveland Clinic Lerner College of Medicine Molecular Medicine program, 07/2021.
14. Co-Instructor, Biostatistics and Epidemiology, two 2-hour lectures. PhD students of Cleveland Clinic Lerner College of Medicine Molecular Medicine program, 05/2022.

RESEARCH / GRANT SUPPORT

Completed

Sponsor Agency and ID #	National Cancer Institute
Title	SPORE in Bladder Cancer
Your Role (PI, Co-PI, Co-Investigator, etc.)	Co-Investigator
Percent Effort	25%
Percent Salary Support	25%
Total Direct Costs Awarded	\$2,299,837
Start-End Dates	08/2018-07/2019

Sponsor Agency and ID #	National Hearth, Lung, and Blood Institute
Title	Investigation of the Effects of Electronic Cigarettes on Vascular Health
Your Role (PI, Co-PI, Co-Investigator, etc.)	Co-Investigator
Percent Effort	5%
Percent Salary Support	5%
Total Direct Costs Awarded	\$128,550
Start-End Dates	09/2016-08/2018

Sponsor Agency and ID #	Chanel Endowment to Fund Survivorship
Title	Body composition and the obesity paradox in renal cell carcinoma
Your Role (PI, Co-PI, Co-Investigator, etc.)	Co-Investigator
Percent Effort	3%
Percent Salary Support	3%
Total Direct Costs Awarded	\$25,941
Start-End Dates	01/2016-06/2019

Sponsor Agency and ID #	MSK Chanel Survivorship Research Grant
Title	Body composition and the obesity paradox in renal cell carcinoma
Your Role (PI, Co-PI, Co-Investigator, etc.)	Co-Investigator
Percent Effort	3%
Percent Salary Support	3%
Total Direct Costs Awarded	\$48,535
Start-End Dates	01/2016-12/2017

Sponsor Agency and ID #	National Cancer Insitute
Title	Do cardiovascular risk factors modify the cardiotoxicity of lymphoma treatments?
Your Role (PI, Co-PI, Co-Investigator, etc.)	Co-Investigator

Percent Effort 12.5%
Percent Salary Support 12.5%
Total Direct Costs Awarded \$50,000
Start-End Dates 06/2015-05/2018

Sponsor Agency and ID # American Cancer Society
Title Predictors of Post-diagnosis Smoking in Bladder Cancer
Your Role (PI, Co-PI, Co-Investigator, etc.) Co-Investigator
Percent Effort 5%
Percent Salary Support 0%
Total Direct Costs Awarded \$156,640
Start-End Dates 01/2015-12/2019

Sponsor Agency and ID # Memorial Sloan Kettering Cancer Center Translational Kidney Cancer Research
Title Immunohistochemical study of estrogen receptor protein expression in ccRCC
Your Role (PI, Co-PI, Co-Investigator, etc.) Co-Investigator
Percent Effort 9%
Percent Salary Support 9%
Total Direct Costs Awarded \$50,000
Start-End Dates 06/2014-11/2015

Sponsor Agency and ID # National Cancer Institute
Title Statistical strategies for Establishing Etiologic Heterogeneity of Tumors
Your Role (PI, Co-PI, Co-Investigator, etc.) Co-Investigator
Percent Effort 40%
Percent Salary Support 40%
Total Direct Costs Awarded \$207,500
Start-End Dates 07/2012-05/2018

BIBLIOGRAPHY

Peer Reviewed Articles

1. **Zabor, E. C.**, Klebanoff, M., Yu, K., Zhang, J., Nansel, T., Andrews, W., Schwebke, J., & Jeffcoat, M. (2010). Association between periodontal disease, bacterial vaginosis, and sexual risk behaviours. *J Clin Periodontol*, 37(10), 888-893. doi:10.1111/j.1600-051X.2010.01593.x
2. Shree, T., Olson, O. C., Elie, B. T., Kester, J. C., Garfall, A. L., Simpson, K., Bell-McGuinn, K. M., **Zabor, E. C.**, Brogi, E., & Joyce, J. A. (2011). Macrophages and cathepsin proteases blunt chemotherapeutic response in breast cancer. *Genes Dev*, 25(23), 2465-2479. doi:10.1101/gad.180331.111
3. Brader, P., Abramson, S. J., Price, A. P., Ishill, N. M., Emily, Z. C., Moskowitz, C. S., La Quaglia, M. P., & Ginsberg, M. S. (2011). Do characteristics of pulmonary nodules on computed tomography in children with known osteosarcoma help distinguish whether the nodules are malignant or benign? *J Pediatr Surg*, 46(4), 729-735. doi:10.1016/j.jpedsurg.2010.11.027
4. Moskowitz, C. S., **Zabor, E. C.**, & Jochelson, M. (2012). Breast imaging: understanding how accuracy is measured when lesions are the unit of analysis. *Breast J*, 18(6), 557-563. doi:10.1111/tbj.12009
5. Kadota, K., Colovos, C., Suzuki, K., Rizk, N. P., Dunphy, M. P., **Zabor, E. C.**, Sima, C. S., Yoshizawa, A., Travis, W. D., Rusch, V. W., & Adusumilli, P. S. (2012). FDG-PET SUVmax combined with IASLC/ATS/ERS histologic classification improves the prognostic stratification of patients with stage I lung adenocarcinoma. *Ann Surg Oncol*, 19(11), 3598-3605. doi:10.1245/s10434-012-2414-3
6. Kadota, K., Suzuki, K., Kachala, S. S., **Zabor, E. C.**, Sima, C. S., Moreira, A. L., Yoshizawa, A., Riely, G. J., Rusch, V. W., Adusumilli, P. S., & Travis, W. D. (2012). A grading system combining architectural features and mitotic count predicts recurrence in stage I lung adenocarcinoma. *Mod Pathol*, 25(8), 1117-1127. doi:10.1038/modpathol.2012.58
7. Begg, C. B., & **Zabor, E. C.** (2012). Detecting and exploiting etiologic heterogeneity in epidemiologic

- studies. *Am J Epidemiol*, 176(6), 512-518. doi:10.1093/aje/kws128
8. Abramson, D. H., Marr, B. P., Dunkel, I. J., Brodie, S., **Zabor, E. C.**, Driscoll, S. J., & Gobin, Y. P. (2012). Intra-arterial chemotherapy for retinoblastoma in eyes with vitreous and/or subretinal seeding: 2-year results. *Br J Ophthalmol*, 96(4), 499-502. doi:10.1136/bjophthalmol-2011-300498
 9. **Zabor, E. C.**, Gonen, M., Chapman, P. B., & Panageas, K. S. (2013). Dynamic prognostication using conditional survival estimates. *Cancer*, 119(20), 3589-3592. doi:10.1002/cncr.28273
 10. **Zabor, E. C.**, Li, Y., Thornton, L. M., Shuman, M. R., Bulik, C. M., Lichtenstein, P., Pedersen, N. L., Sullivan, P. F., & Furberg, H. (2013). Initial reactions to tobacco use and risk of future regular use. *Nicotine Tob Res*, 15(2), 509-517. doi:10.1093/ntr/nts180
 11. Weiss, M. J., Ito, H., Araujo, R. L., **Zabor, E. C.**, Gonen, M., D'Angelica, M. I., Allen, P. J., DeMatteo, R. P., Fong, Y., Blumgart, L. H., & Jarnagin, W. R. (2013). Hepatic pedicle clamping during hepatic resection for colorectal liver metastases: no impact on survival or hepatic recurrence. *Ann Surg Oncol*, 20(1), 285-294. doi:10.1245/s10434-012-2583-0
 12. Rink, M., **Zabor, E. C.**, Furberg, H., Xylinas, E., Ehdaie, B., Novara, G., Babjuk, M., Pycha, A., Lotan, Y., Trinh, Q. D., Chun, F. K., Lee, R. K., Karakiewicz, P. I., Fisch, M., Robinson, B. D., Scherr, D. S., & Shariat, S. F. (2013). Impact of smoking and smoking cessation on outcomes in bladder cancer patients treated with radical cystectomy. *Eur Urol*, 64(3), 456-464. doi:10.1016/j.eururo.2012.11.039
 13. Rink, M., Furberg, H., **Zabor, E. C.**, Xylinas, E., Babjuk, M., Pycha, A., Lotan, Y., Karakiewicz, P. I., Novara, G., Robinson, B. D., Montorsi, F., Chun, F. K., Scherr, D. S., & Shariat, S. F. (2013). Impact of smoking and smoking cessation on oncologic outcomes in primary non-muscle-invasive bladder cancer. *Eur Urol*, 63(4), 724-732. doi:10.1016/j.eururo.2012.08.025
 14. Ridge, C. A., Huang, J., Cardoza, S., **Zabor, E. C.**, Moskowitz, C. S., Zakowski, M. F., & Ginsberg, M. S. (2013). Comparison of multiplanar reformatted CT lung tumor measurements to axial tumor measurement alone: impact on maximal tumor dimension and T stage. *AJR Am J Roentgenol*, 201(5), 959-963. doi:10.2214/ajr.12.10033
 15. Pannu, H. K., Ma, W., **Zabor, E. C.**, Moskowitz, C. S., Barakat, R. R., & Hricak, H. (2013). Enhancement of ovarian malignancy on clinical contrast enhanced MRI studies. *ISRN Obstet Gynecol*, 2013, 979345. doi:10.1155/2013/979345
 16. McErlean, A., Panicek, D. M., **Zabor, E. C.**, Moskowitz, C. S., Bitar, R., Motzer, R. J., Hricak, H., & Ginsberg, M. S. (2013). Intra- and interobserver variability in CT measurements in oncology. *Radiology*, 269(2), 451-459. doi:10.1148/radiol.13122665
 17. McErlean, A., Huang, J., **Zabor, E. C.**, Moskowitz, C. S., & Ginsberg, M. S. (2013). Distinguishing benign thymic lesions from early-stage thymic malignancies on computed tomography. *J Thorac Oncol*, 8(7), 967-973. doi:10.1097/JTO.0b013e3182904bc2
 18. Lefkowitz, R. A., Landa, J., Hwang, S., **Zabor, E. C.**, Moskowitz, C. S., Agaram, N. P., & Panicek, D. M. (2013). Myxofibrosarcoma: prevalence and diagnostic value of the "tail sign" on magnetic resonance imaging. *Skeletal Radiol*, 42(6), 809-818. doi:10.1007/s00256-012-1563-6
 19. Iyer, G., Al-Ahmadie, H., Schultz, N., Hanrahan, A. J., Ostrovnaya, I., Balar, A. V., Kim, P. H., Lin, O., Weinhold, N., Sander, C., **Zabor, E. C.**, Janakiraman, M., Garcia-Grossman, I. R., Heguy, A., Viale, A., Bochner, B. H., Reuter, V. E., Bajorin, D. F., Milowsky, M. I., Taylor, B. S., & Solit, D. B. (2013). Prevalence and co-occurrence of actionable genomic alterations in high-grade bladder cancer. *J Clin Oncol*, 31(25), 3133-3140. doi:10.1200/jco.2012.46.5740
 20. Hakimi, A. A., Furberg, H., **Zabor, E. C.**, Jacobsen, A., Schultz, N., Ciriello, G., Mikklineni, N., Fiegoli, B., Kim, P. H., Voss, M. H., Shen, H., Laird, P. W., Sander, C., Reuter, V. E., Motzer, R. J., Hsieh, J. J., & Russo, P. (2013). An epidemiologic and genomic investigation into the obesity paradox in renal cell carcinoma. *J Natl Cancer Inst*, 105(24), 1862-1870. doi:10.1093/jnci/djt310
 21. Ehdaie, B., Furberg, H., **Zabor, E. C.**, Ostroff, J. S., Shariat, S. F., Bochner, B. H., Coleman, J. A., & Dalbagni, G. (2013). Impact of smoking status at diagnosis on disease recurrence and death in upper tract urothelial carcinoma. *BJU Int*, 111(4), 589-595. doi:10.1111/j.1464-410X.2012.11260.x
 22. Begg, C. B., **Zabor, E. C.**, Bernstein, J. L., Bernstein, L., Press, M. F., & Seshan, V. E. (2013). A conceptual and methodological framework for investigating etiologic heterogeneity. *Stat Med*, 32(29), 5039-5052. doi:10.1002/sim.5902
 23. Sfakianos, J. P., Hakimi, A. A., Kim, P. H., **Zabor, E. C.**, Mano, R., Bernstein, M., Karellas, M., & Russo, P. (2014). Outcomes in patients undergoing nephrectomy for renal cancer on chronic anticoagulation therapy. *Eur J Surg Oncol*, 40(12), 1700-1705. doi:10.1016/j.ejso.2014.04.010
 24. Mano, R., Hakimi, A. A., **Zabor, E. C.**, Bury, M. A., Donati, O. F., Karlo, C. A., Bazzi, W. M., Furberg,

- H., & Russo, P. (2014). Association between visceral and subcutaneous adiposity and clinicopathological outcomes in non-metastatic clear cell renal cell carcinoma. *Can Urol Assoc J*, 8(9-10), E675-680. doi:10.5489/cuaj.1979
25. Lubetkin, E. I., **Zabor, E. C.**, Brennessel, D., Kemeny, M. M., & Hay, J. L. (2014). Beyond demographics: differences in patient activation across new immigrant, diverse language subgroups. *J Community Health*, 39(1), 40-49. doi:10.1007/s10900-013-9738-1
 26. Hayes, S. A., Soff, G. A., **Zabor, E. C.**, Moskowitz, C. S., Liu, C. C., & Ginsberg, M. S. (2014). Clinical consequences of an indeterminate CT pulmonary angiogram in cancer patients. *Clin Imaging*, 38(5), 637-640. doi:10.1016/j.clinimag.2014.04.015
 27. Ehdaie, B., Furberg, H., **Zabor, E. C.**, Hakimi, A. A., & Russo, P. (2014). Comprehensive assessment of the impact of cigarette smoking on survival of clear cell kidney cancer. *J Urol*, 191(3), 597-602. doi:10.1016/j.juro.2013.08.081
 28. Do, R. K., Katz, S. S., Gollub, M. J., Li, J., LaFemina, J., **Zabor, E. C.**, Moskowitz, C. S., Klimstra, D. S., & Allen, P. J. (2014). Interobserver agreement for detection of malignant features of intraductal papillary mucinous neoplasms of the pancreas on MDCT. *AJR Am J Roentgenol*, 203(5), 973-979. doi:10.2214/ajr.13.11490
 29. Begg, C. B., Seshan, V. E., **Zabor, E. C.**, Furberg, H., Arora, A., Shen, R., Maranchie, J. K., Nielsen, M. E., Rathmell, W. K., Signoretti, S., Tamboli, P., Karam, J. A., Choueiri, T. K., Hakimi, A. A., & Hsieh, J. J. (2014). Genomic investigation of etiologic heterogeneity: methodologic challenges. *BMC Med Res Methodol*, 14, 138. doi:10.1186/1471-2288-14-138
 30. Sfakianos, J. P., Cha, E. K., Iyer, G., Scott, S. N., **Zabor, E. C.**, Shah, R. H., Ren, Q., Bagrodia, A., Kim, P. H., Hakimi, A. A., Ostrovnaya, I., Ramirez, R., Hanrahan, A. J., Desai, N. B., Sun, A., Pinciroli, P., Rosenberg, J. E., Dalbagni, G., Schultz, N., Bajorin, D. F., Reuter, V. E., Berger, M. F., Bochner, B. H., Al-Ahmadie, H. A., Solit, D. B., & Coleman, J. A. (2015). Genomic Characterization of Upper Tract Urothelial Carcinoma. *Eur Urol*, 68(6), 970-977. doi:10.1016/j.eururo.2015.07.039
 31. Lubetkin, E. I., **Zabor, E. C.**, Isaac, K., Brennessel, D., Kemeny, M. M., & Hay, J. L. (2015). Health literacy, information seeking, and trust in information in Haitians. *Am J Health Behav*, 39(3), 441-450. doi:10.5993/ajhb.39.3.16
 32. Kim, P. H., Cha, E. K., Sfakianos, J. P., Iyer, G., **Zabor, E. C.**, Scott, S. N., Ostrovnaya, I., Ramirez, R., Sun, A., Shah, R., Yee, A. M., Reuter, V. E., Bajorin, D. F., Rosenberg, J. E., Schultz, N., Berger, M. F., Al-Ahmadie, H. A., Solit, D. B., & Bochner, B. H. (2015). Genomic predictors of survival in patients with high-grade urothelial carcinoma of the bladder. *Eur Urol*, 67(2), 198-201. doi:10.1016/j.eururo.2014.06.050
 33. Begg, C. B., Orlow, I., **Zabor, E. C.**, Arora, A., Sharma, A., Seshan, V. E., & Bernstein, J. L. (2015). Identifying Etiologically Distinct Sub-Types of Cancer: A Demonstration Project Involving Breast Cancer. *Cancer Med*, 4(9), 1432-1439. doi:10.1002/cam4.456
 34. Bambury, R. M., Benjamin, D. J., Chaim, J. L., **Zabor, E. C.**, Sullivan, J., Garcia-Grossman, I. R., Regazzi, A. M., Ostrovnaya, I., Apollo, A., Xiao, H., Voss, M. H., Iyer, G., Bajorin, D. F., & Rosenberg, J. E. (2015). The safety and efficacy of single-agent pemetrexed in platinum-resistant advanced urothelial carcinoma: a large single-institution experience. *Oncologist*, 20(5), 508-515. doi:10.1634/theoncologist.2014-0354
 35. **Zabor, E. C.**, Furberg, H., Mashni, J., Lee, B., Jaimes, E. A., & Russo, P. (2016). Factors Associated with Recovery of Renal Function following Radical Nephrectomy for Kidney Neoplasms. *Clin J Am Soc Nephrol*, 11(1), 101-107. doi:10.2215/cjn.04070415
 36. **Zabor, E. C.**, Heller, G., Schwartz, L. H., & Chapman, P. B. (2016). Correlating Surrogate Endpoints with Overall Survival at the Individual Patient Level in BRAFV600E-Mutated Metastatic Melanoma Patients Treated with Vemurafenib. *Clin Cancer Res*, 22(6), 1341-1347. doi:10.1158/1078-0432.Ccr-15-1441
 37. Yu, A. F., Raikhelkar, J., **Zabor, E. C.**, Tonorezos, E. S., Moskowitz, C. S., Adsuar, R., Mara, E., Huie, K., Oeffinger, K. C., Steingart, R. M., & Liu, J. E. (2016). Two-Dimensional Speckle Tracking Echocardiography Detects Subclinical Left Ventricular Systolic Dysfunction among Adult Survivors of Childhood, Adolescent, and Young Adult Cancer. *Biomed Res Int*, 2016, 9363951. doi:10.1155/2016/9363951
 38. Tully, C. M., Apolo, A. B., **Zabor, E. C.**, Regazzi, A. M., Ostrovnaya, I., Furberg, H. F., Rosenberg, J. E., & Bajorin, D. F. (2016). The high incidence of vascular thromboembolic events in patients with metastatic or unresectable urothelial cancer treated with platinum chemotherapy agents. *Cancer*, 122(5), 712-721. doi:10.1002/cncr.29801

39. Thong, A. E., Petruzella, S., Orlow, I., **Zabor, E. C.**, Ehdaie, B., Ostroff, J. S., Bochner, B. H., & Furberg Barnes, H. (2016). Accuracy of Self-reported Smoking Exposure Among Bladder Cancer Patients Undergoing Surveillance at a Tertiary Referral Center. *Eur Urol Focus*, 2(4), 441-444. doi:10.1016/j.euf.2015.12.002
40. Thong, A. E., Petruzella, S., Orlow, I., **Zabor, E. C.**, Ehdaie, B., Ostroff, J. S., Bochner, B. H., & Barnes, H. F. (2016). Accuracy of Self-reported Smoking Exposure Among Bladder Cancer Patients Undergoing Surveillance at a Tertiary Referral Center. *Eur Urol Focus*, 2(4), 441-444. doi:10.1016/j.euf.2015.12.002
41. Spitzer, B., Perales, M. A., Kernan, N. A., Prockop, S. E., **Zabor, E. C.**, Webb, N., Castro-Malaspina, H., Papadopoulos, E. B., Young, J. W., Scaradavou, A., Kobos, R., Giralt, S. A., O'Reilly, R. J., & Boulad, F. (2016). Second Allogeneic Stem Cell Transplantation for Acute Leukemia Using a Chemotherapy-Only Cytoreduction with Clofarabine, Melphalan, and Thiotepa. *Biol Blood Marrow Transplant*, 22(8), 1449-1454. doi:10.1016/j.bbmt.2016.05.001
42. Murray, K. S., **Zabor, E. C.**, Spaliviero, M., Russo, P., Bazzi, W. M., Musser, J. E., Ari Hakimi, A., Bernstein, M. L., Dalbagni, G., Coleman, J. A., & Furberg, H. (2016). Second primary malignancies in renal cortical neoplasms: an updated evaluation from a single institution. *World J Urol*, 34(12), 1667-1672. doi:10.1007/s00345-016-1832-4
43. Hay, J. L., **Zabor, E. C.**, Kumar, J., Brennessel, D., Kemeny, M. M., & Lubetkin, E. I. (2016). Cancer beliefs and patient activation in a diverse, multilingual primary care sample. *Psychooncology*, 25(9), 1071-1078. doi:10.1002/pon.4196
44. Desai, N. B., Scott, S. N., **Zabor, E. C.**, Cha, E. K., Hreiki, J., Sfakianos, J. P., Ramirez, R., Bagrodia, A., Rosenberg, J. E., Bajorin, D. F., Berger, M. F., Bochner, B. H., Zelefsky, M. J., Kollmeier, M. A., Ostrovnaya, I., Al-Ahmadie, H. A., Solit, D. B., & Iyer, G. (2016). Genomic characterization of response to chemoradiation in urothelial bladder cancer. *Cancer*, 122(23), 3715-3723. doi:10.1002/cncr.30219
45. Dahi, P. B., Morawa, E., Perales, M. A., **Zabor, E. C.**, Devlin, S. M., Maloy, M., Castro-Malaspina, H., O'Reilly, R. J., Papadopoulos, E. B., Jakubowski, A. A., & Giralt, S. A. (2016). Low incidence of GvHD with T-cell depleted allografts facilitates further treatments for post-transplantation relapse in AML and MDS. *Bone Marrow Transplant*, 51(7), 991-993. doi:10.1038/bmt.2016.23
46. Bagrodia, A., Lee, B. H., Lee, W., Cha, E. K., Sfakianos, J. P., Iyer, G., Pietzak, E. J., Gao, S. P., **Zabor, E. C.**, Ostrovnaya, I., Kaffenberger, S. D., Syed, A., Arcila, M. E., Chaganti, R. S., Kundra, R., Eng, J., Hreiki, J., Vacic, V., Arora, K., Oschwald, D. M., Berger, M. F., Bajorin, D. F., Bains, M. S., Schultz, N., Reuter, V. E., Sheinfeld, J., Bosl, G. J., Al-Ahmadie, H. A., Solit, D. B., & Feldman, D. R. (2016). Genetic Determinants of Cisplatin Resistance in Patients With Advanced Germ Cell Tumors. *J Clin Oncol*, 34(33), 4000-4007. doi:10.1200/jco.2016.68.7798
47. Bagrodia, A., Cha, E. K., Sfakianos, J. P., **Zabor, E. C.**, Bochner, B. H., Al-Ahmadie, H. A., Solit, D. B., Coleman, J. A., Iyer, G., Scott, S. N., Shah, R., Ostrovnaya, I., Lee, B., Desai, N. B., Ren, Q., Rosenberg, J. E., Dalbagni, G., Bajorin, D. F., Reuter, V. E., & Berger, M. F. (2016). Genomic Biomarkers for the Prediction of Stage and Prognosis of Upper Tract Urothelial Carcinoma. *J Urol*, 195(6), 1684-1689. doi:10.1016/j.juro.2016.01.006
48. Albiges, L., Hakimi, A. A., Xie, W., McKay, R. R., Simantov, R., Lin, X., Lee, J. L., Rini, B. I., Srinivas, S., Bjarnason, G. A., Ernst, S., Wood, L. A., Vaishamayan, U. N., Rha, S. Y., Agarwal, N., Yuasa, T., Pal, S. K., Bamias, A., **Zabor, E. C.**, Skanderup, A. J., Furberg, H., Fay, A. P., de Velasco, G., Preston, M. A., Wilson, K. M., Cho, E., McDermott, D. F., Signoretti, S., Heng, D. Y. C., & Choueiri, T. K. (2016). Body Mass Index and Metastatic Renal Cell Carcinoma: Clinical and Biological Correlations. *J Clin Oncol*, 34(30), 3655-3663. doi:10.1200/jco.2016.66.7311
49. Al-Ahmadie, H. A., Iyer, G., Lee, B. H., Scott, S. N., Mehra, R., Bagrodia, A., Jordan, E. J., Gao, S. P., Ramirez, R., Cha, E. K., Desai, N. B., **Zabor, E. C.**, Ostrovnaya, I., Gopalan, A., Chen, Y. B., Fine, S. W., Tickoo, S. K., Gandhi, A., Hreiki, J., Viale, A., Arcila, M. E., Dalbagni, G., Rosenberg, J. E., Bochner, B. H., Bajorin, D. F., Berger, M. F., Reuter, V. E., Taylor, B. S., & Solit, D. B. (2016). Frequent somatic CDH1 loss-of-function mutations in plasmacytoid variant bladder cancer. *Nat Genet*, 48(4), 356-358. doi:10.1038/ng.3503
50. **Zabor, E. C.**, & Begg, C. B. (2017). A comparison of statistical methods for the study of etiologic heterogeneity. *Stat Med*, 36(25), 4050-4060. doi:10.1002/sim.7405
51. Weber, J. J., Jochelson, M. S., Eaton, A., **Zabor, E. C.**, Barrio, A. V., Gemignani, M. L., Pilewskie, M., Van Zee, K. J., Morrow, M., & El-Tamer, M. (2017). MRI and Prediction of Pathologic Complete Response in the Breast and Axilla after Neoadjuvant Chemotherapy for Breast Cancer. *J Am Coll Surg*, 225(6), 740-746. doi:10.1016/j.jamcollsurg.2017.08.027

52. Teo, M. Y., Bambury, R. M., **Zabor, E. C.**, Jordan, E., Al-Ahmadie, H., Boyd, M. E., Bouvier, N., Mullane, S. A., Cha, E. K., Roper, N., Ostrovnaya, I., Hyman, D. M., Bochner, B. H., Arcila, M. E., Solit, D. B., Berger, M. F., Bajorin, D. F., Bellmunt, J., Iyer, G., & Rosenberg, J. E. (2017). DNA Damage Response and Repair Gene Alterations Are Associated with Improved Survival in Patients with Platinum-Treated Advanced Urothelial Carcinoma. *Clin Cancer Res*, 23(14), 3610-3618. doi:10.1158/1078-0432.Ccr-16-2520
53. Schwitzer, E., Orlow, I., **Zabor, E. C.**, Begg, C. B., Berwick, M., Thomas, N. E., Kanetsky, P. A., & Jones, L. W. (2017). No association between prediagnosis exercise and survival in patients with high-risk primary melanoma: A population-based study. *Pigment Cell Melanoma Res*, 30(4), 424-427. doi:10.1111/pcmr.12594
54. Salz, T., **Zabor, E. C.**, de Nully Brown, P., Dalton, S. O., Raghunathan, N. J., Matasar, M. J., Steingart, R., Vickers, A. J., Svenssen Munksgaard, P., Oeffinger, K. C., & Johansen, C. (2017). Preexisting Cardiovascular Risk and Subsequent Heart Failure Among Non-Hodgkin Lymphoma Survivors. *J Clin Oncol*, 35(34), 3837-3843. doi:10.1200/jco.2017.72.4211
55. Pilewskie, M., **Zabor, E. C.**, Mamtani, A., Barrio, A. V., Stempel, M., & Morrow, M. (2017). The Optimal Treatment Plan to Avoid Axillary Lymph Node Dissection in Early-Stage Breast Cancer Patients Differs by Surgical Strategy and Tumor Subtype. *Ann Surg Oncol*, 24(12), 3527-3533. doi:10.1245/s10434-017-6016-y
56. McCartan, D. P., **Zabor, E. C.**, Morrow, M., Van Zee, K. J., & El-Tamer, M. B. (2017). Oncologic Outcomes After Treatment for MRI Occult Breast Cancer (pT0N+). *Ann Surg Oncol*, 24(11), 3141-3147. doi:10.1245/s10434-017-5965-5
57. Mauguen, A., **Zabor, E. C.**, Thomas, N. E., Berwick, M., Seshan, V. E., & Begg, C. B. (2017). Defining Cancer Subtypes With Distinctive Etiologic Profiles: An Application to the Epidemiology of Melanoma. *J Am Stat Assoc*, 112(517), 54-63. doi:10.1080/01621459.2016.1191499
58. Manley, B. J., **Zabor, E. C.**, Casuscelli, J., Tennenbaum, D. M., Redzematovic, A., Becerra, M. F., Benfante, N., Sato, Y., Morikawa, T., Kume, H., Fukayama, M., Homma, Y., Ogawa, S., Arcila, M. E., Voss, M. H., Feldman, D. R., Coleman, J. A., Reuter, V. E., Motzer, R. J., Russo, P., Hsieh, J. J., & Hakimi, A. A. (2017). Integration of Recurrent Somatic Mutations with Clinical Outcomes: A Pooled Analysis of 1049 Patients with Clear Cell Renal Cell Carcinoma. *Eur Urol Focus*, 3(4-5), 421-427. doi:10.1016/j.euf.2016.06.015
59. Gilbert, E., **Zabor, E. C.**, Stempel, M., Mangino, D., Heerdt, A., & Pilewskie, M. (2017). Differences Among a Modern Cohort of BRCA Mutation Carriers Choosing Bilateral Prophylactic Mastectomies Compared to Breast Surveillance. *Ann Surg Oncol*, 24(10), 3048-3054. doi:10.1245/s10434-017-5976-2
60. Gentile, L. F., Plitas, G., **Zabor, E. C.**, Stempel, M., Morrow, M., & Barrio, A. V. (2017). Tumor Biology Predicts Pathologic Complete Response to Neoadjuvant Chemotherapy in Patients Presenting with Locally Advanced Breast Cancer. *Ann Surg Oncol*, 24(13), 3896-3902. doi:10.1245/s10434-017-6085-y
61. Francis, J. H., Brodie, S. E., Marr, B., **Zabor, E. C.**, Mondesire-Crump, I., & Abramson, D. H. (2017). Efficacy and Toxicity of Intravitreal Chemotherapy for Retinoblastoma: Four-Year Experience. *Ophthalmology*, 124(4), 488-495. doi:10.1016/j.ophtha.2016.12.015
62. Cho, G. Y., Gennaro, L., Sutton, E. J., **Zabor, E. C.**, Zhang, Z., Giri, D., Moy, L., Sodickson, D. K., Morris, E. A., Sigmund, E. E., & Thakur, S. B. (2017). Intravoxel incoherent motion (IVIM) histogram biomarkers for prediction of neoadjuvant treatment response in breast cancer patients. *Eur J Radiol Open*, 4, 101-107. doi:10.1016/j.ejro.2017.07.002
63. Casuscelli, J., Weinhold, N., Gudem, G., Wang, L., **Zabor, E. C.**, Drill, E., Wang, P. I., Nanjangud, G. J., Redzematovic, A., Nargund, A. M., Manley, B. J., Arcila, M. E., Donin, N. M., Cheville, J. C., Thompson, R. H., Pantuck, A. J., Russo, P., Cheng, E. H., Lee, W., Tickoo, S. K., Ostrovnaya, I., Creighton, C. J., Papaemmanuil, E., Seshan, V. E., Hakimi, A. A., & Hsieh, J. J. (2017). Genomic landscape and evolution of metastatic chromophobe renal cell carcinoma. *JCI Insight*, 2(12). doi:10.1172/jci.insight.92688
64. Campbell, P. T., Rebbeck, T. R., Nishihara, R., Beck, A. H., Begg, C. B., Bogdanov, A. A., Cao, Y., Coleman, H. G., Freeman, G. J., Heng, Y. J., Huttenhower, C., Irizarry, R. A., Kip, N. S., Michor, F., Nevo, D., Peters, U., Phipps, A. I., Poole, E. M., Qian, Z. R., Quackenbush, J., Robins, H., Rogan, P. K., Slattery, M. L., Smith-Warner, S. A., Song, M., VanderWeele, T. J., Xia, D., **Zabor, E. C.**, Zhang, X., Wang, M., & Ogino, S. (2017). Proceedings of the third international molecular pathological epidemiology (MPE) meeting. *Cancer Causes Control*, 28(2), 167-176. doi:10.1007/s10552-016-0845-z
65. Boursiquot, B. C., **Zabor, E. C.**, Glezerman, I. G., & Jaimes, E. A. (2017). Hypertension and VEGF (Vascular Endothelial Growth Factor) Receptor Tyrosine Kinase Inhibition: Effects on Renal Function.

Hypertension. doi:10.1161/hypertensionaha.117.09275

66. Begg, C. B., Rice, M. S., **Zabor, E. C.**, & Tworoger, S. S. (2017). Examining the common aetiology of serous ovarian cancers and basal-like breast cancers using double primaries. *Br J Cancer*, *116*(8), 1088-1091. doi:10.1038/bjc.2017.73
67. Alane, S. R., Shah, S., **Zabor, E. C.**, Vijai, J., Ostrovnaya, I., Garcia-Grossman, I. R., Pendse, D. V., Littman, J., Regazzi, A. M., Offit, K., & Bajorin, D. F. (2017). Evaluating the association of multiple single nucleotide polymorphisms with response to gemcitabine and platinum combination chemotherapy in urothelial carcinoma of the bladder. *Int J Clin Pharmacol Ther*, *55*(3), 203-209. doi:10.5414/cp202856
68. **Zabor, E. C.**, Coit, D., Gershenwald, J. E., McMasters, K. M., Michaelson, J. S., Stromberg, A. J., & Panageas, K. S. (2018). Variability in Predictions from Online Tools: A Demonstration Using Internet-Based Melanoma Predictors. *Ann Surg Oncol*, *25*(8), 2172-2177. doi:10.1245/s10434-018-6370-4
69. **Zabor, E. C.**, Furberg, H., Lee, B., Campbell, S., Lane, B. R., Thompson, R. H., Antonio, E. C., Noyes, S. L., Zaid, H., Jaimes, E. A., & Russo, P. (2018). Long-Term Renal Function Recovery following Radical Nephrectomy for Kidney Cancer: Results from a Multicenter Confirmatory Study. *J Urol*, *199*(4), 921-926. doi:10.1016/j.juro.2017.10.027
70. Winer, A. G., **Zabor, E. C.**, Vacchio, M. J., Hakimi, A. A., Russo, P., Coleman, J. A., & Jaimes, E. A. (2018). The Effect of Patient and Surgical Characteristics on Renal Function After Partial Nephrectomy. *Clin Genitourin Cancer*, *16*(3), 191-196. doi:10.1016/j.clgc.2017.11.006
71. Silk, M. T., Mikkilineni, N., Silk, T. C., **Zabor, E. C.**, Ostrovnaya, I., Hakimi, A. A., Hsieh, J. J., Ziv, E., Rekhman, N., Solomon, S. B., & Durack, J. C. (2018). Prospective Evaluation of Unprocessed Core Needle Biopsy DNA and RNA Yield from Lung, Liver, and Kidney Tumors: Implications for Cancer Genomics. *Anal Cell Pathol (Amst)*, *2018*, 2898962. doi:10.1155/2018/2898962
72. Scott, J. M., **Zabor, E. C.**, Schwitzer, E., Koelwyn, G. J., Adams, S. C., Nilsen, T. S., Moskowitz, C. S., Matsoukas, K., Iyengar, N. M., Dang, C. T., & Jones, L. W. (2018). Efficacy of Exercise Therapy on Cardiorespiratory Fitness in Patients With Cancer: A Systematic Review and Meta-Analysis. *J Clin Oncol*, *36*(22), 2297-2305. doi:10.1200/jco.2017.77.5809
73. Romanoff, A., **Zabor, E. C.**, Petruolo, O., Stempel, M., El-Tamer, M., Morrow, M., & Barrio, A. V. (2018). Does nonmetastatic inflammatory breast cancer have a worse prognosis than other nonmetastatic T4 cancers? *Cancer*, *124*(22), 4314-4321. doi:10.1002/cncr.31757
74. Romanoff, A., **Zabor, E. C.**, Stempel, M., Sacchini, V., Pusic, A., & Morrow, M. (2018). A Comparison of Patient-Reported Outcomes After Nipple-Sparing Mastectomy and Conventional Mastectomy with Reconstruction. *Ann Surg Oncol*, *25*(10), 2909-2916. doi:10.1245/s10434-018-6585-4
75. Moo, T. A., Edelweiss, M., Hajiyeva, S., Stempel, M., Raiss, M., **Zabor, E. C.**, Barrio, A., & Morrow, M. (2018). Is Low-Volume Disease in the Sentinel Node After Neoadjuvant Chemotherapy an Indication for Axillary Dissection? *Ann Surg Oncol*, *25*(6), 1488-1494. doi:10.1245/s10434-018-6429-2
76. Lee, B. H., **Zabor, E. C.**, Tennenbaum, D., Furberg, H., Benfante, N., Coleman, J. A., Jaimes, E. A., & Russo, P. (2018). Renal function recovery after radical nephroureterectomy for upper tract urothelial carcinoma. *World J Urol*, *36*(2), 257-263. doi:10.1007/s00345-017-2139-9
77. Francis, J. H., Levin, A. M., **Zabor, E. C.**, Gobin, Y. P., & Abramson, D. H. (2018). Ten-year experience with ophthalmic artery chemosurgery: Ocular and recurrence-free survival. *PLoS One*, *13*(5), e0197081. doi:10.1371/journal.pone.0197081
78. Cronin, P. A., Romanoff, A., **Zabor, E. C.**, Stempel, M., Eaton, A., Smyth, L. M., Ho, A. Y., Morrow, M., El-Tamer, M., & Gemignani, M. L. (2018). Influence of Age on the Clinical Outcome of Breast Cancer for Men and the Development of Second Primary Cancers. *Ann Surg Oncol*, *25*(13), 3858-3866. doi:10.1245/s10434-018-6767-0
79. Cassidy, M. R., **Zabor, E. C.**, Stempel, M., Mehrara, B., & Gemignani, M. L. (2018). Does response to neo-adjuvant chemotherapy impact breast reconstruction? *Breast J*, *24*(4), 567-573. doi:10.1111/tbj.12977
80. Walsh, S. M., Brennan, S. B., **Zabor, E. C.**, Rosenberger, L. H., Stempel, M., Lebron-Zapata, L., & Gemignani, M. L. (2019). Does Breast Density Increase the Risk of Re-excision for Women with Breast Cancer Having Breast-Conservation Therapy? *Ann Surg Oncol*, *26*(13), 4246-4253. doi:10.1245/s10434-019-07647-7
81. Walsh, S. M., **Zabor, E. C.**, Stempel, M., Morrow, M., & Gemignani, M. L. (2019). Does race predict survival for women with invasive breast cancer? *Cancer*, *125*(18), 3139-3146. doi:10.1002/cncr.32296
82. Van Zee, K. J., **Zabor, E. C.**, Di Donato, R., Harmon, B., Fox, J., Morrow, M., Cody, H. S., 3rd, & Fineberg, S. A. (2019). Comparison of Local Recurrence Risk Estimates After Breast-Conserving Surgery for DCIS: DCIS Nomogram Versus Refined Oncotype DX Breast DCIS Score. *Ann Surg Oncol*, *26*(10),

- 3282-3288. doi:10.1245/s10434-019-07537-y
83. Spanheimer, P. M., Murray, M. P., **Zabor, E. C.**, Stempel, M., Morrow, M., Van Zee, K. J., & Barrio, A. V. (2019). Long-Term Outcomes After Surgical Treatment of Malignant/Borderline Phyllodes Tumors of the Breast. *Ann Surg Oncol*, 26(7), 2136-2143. doi:10.1245/s10434-019-07210-4
 84. Pilewskie, M., **Zabor, E. C.**, Gilbert, E., Stempel, M., Petruolo, O., Mangino, D., Robson, M., & Jochelson, M. S. (2019). Differences between screen-detected and interval breast cancers among BRCA mutation carriers. *Breast Cancer Res Treat*, 175(1), 141-148. doi:10.1007/s10549-018-05123-6
 85. Pietzak, E. J., **Zabor, E. C.**, Bagrodia, A., Armenia, J., Hu, W., Zehir, A., Funt, S., Audenet, F., Barron, D., Maamouri, N., Li, Q., Teo, M. Y., Arcila, M. E., Berger, M. F., Schultz, N., Dalbagni, G., Herr, H. W., Bajorin, D. F., Rosenberg, J. E., Al-Ahmadie, H., Bochner, B. H., Solit, D. B., & Iyer, G. (2019). Genomic Differences Between "Primary" and "Secondary" Muscle-invasive Bladder Cancer as a Basis for Disparate Outcomes to Cisplatin-based Neoadjuvant Chemotherapy. *Eur Urol*, 75(2), 231-239. doi:10.1016/j.eururo.2018.09.002
 86. Moo, T. A., Jochelson, M. S., **Zabor, E. C.**, Stempel, M., Raiss, M., Mamtani, A., Tadros, A. B., El-Tamer, M., & Morrow, M. (2019). Is Clinical Exam of the Axilla Sufficient to Select Node-Positive Patients Who Downstage After NAC for SLNB? A Comparison of the Accuracy of Clinical Exam Versus MRI. *Ann Surg Oncol*, 26(13), 4238-4243. doi:10.1245/s10434-019-07867-x
 87. Miller, M. E., Muhsen, S., **Zabor, E. C.**, Flynn, J., Olcese, C., Giri, D., Van Zee, K. J., & Pilewskie, M. (2019). Risk of Contralateral Breast Cancer in Women with Ductal Carcinoma In Situ Associated with Synchronous Ipsilateral Lobular Carcinoma In Situ. *Ann Surg Oncol*, 26(13), 4317-4325. doi:10.1245/s10434-019-07796-9
 88. Mamtani, A., **Zabor, E. C.**, Rosenberger, L. H., Stempel, M., Gemignani, M. L., & Morrow, M. (2019). Was Reexcision Less Frequent for Patients with Lobular Breast Cancer After Publication of the SSO-ASTRO Margin Guidelines? *Ann Surg Oncol*, 26(12), 3856-3862. doi:10.1245/s10434-019-07751-8
 89. Mamtani, A., Nakhlis, F., Downs-Canner, S., **Zabor, E. C.**, Morrow, M., King, T. A., & Van Zee, K. J. (2019). Impact of Age on Locoregional and Distant Recurrence After Mastectomy for Ductal Carcinoma In Situ With or Without Microinvasion. *Ann Surg Oncol*, 26(13), 4264-4271. doi:10.1245/s10434-019-07693-1
 90. Mamtani, A., **Zabor, E. C.**, Stempel, M., & Morrow, M. (2019). Lobular Histology Does Not Predict the Need for Axillary Dissection Among ACOSOG Z0011-Eligible Breast Cancers. *Ann Surg Oncol*, 26(10), 3269-3274. doi:10.1245/s10434-019-07536-z
 91. Grabenstetter, A., Moo, T. A., Hajiyeva, S., Schüffler, P. J., Khattar, P., Friedlander, M. A., McCormack, M. A., Raiss, M., **Zabor, E. C.**, Barrio, A., Morrow, M., & Edelweiss, M. (2019). Accuracy of Intraoperative Frozen Section of Sentinel Lymph Nodes After Neoadjuvant Chemotherapy for Breast Carcinoma. *Am J Surg Pathol*, 43(10), 1377-1383. doi:10.1097/pas.0000000000001311
 92. Flanagan, M. R., **Zabor, E. C.**, Romanoff, A., Fuzesi, S., Stempel, M., Mehrara, B. J., Morrow, M., Pusic, A. L., & Gemignani, M. L. (2019). A Comparison of Patient-Reported Outcomes After Breast-Conserving Surgery and Mastectomy with Implant Breast Reconstruction. *Ann Surg Oncol*, 26(10), 3133-3140. doi:10.1245/s10434-019-07548-9
 93. Flanagan, M. R., **Zabor, E. C.**, Stempel, M., Mangino, D. A., Morrow, M., & Pilewskie, M. L. (2019). Chemoprevention Uptake for Breast Cancer Risk Reduction Varies by Risk Factor. *Ann Surg Oncol*, 26(7), 2127-2135. doi:10.1245/s10434-019-07236-8
 94. Engel, L. S., **Zabor, E. C.**, Satagopan, J., Widell, A., Rothman, N., O'Brien, T. R., Zhang, M., Van Den Eeden, S. K., & Grimsrud, T. K. (2019). Prediagnostic serum organochlorine insecticide concentrations and primary liver cancer: A case-control study nested within two prospective cohorts. *Int J Cancer*, 145(9), 2360-2371. doi:10.1002/ijc.32175
 95. Downs-Canner, S., **Zabor, E. C.**, Wind, T., Cobovic, A., McCormick, B., Morrow, M., & Heerdt, A. (2019). Radiation Therapy After Breast-Conserving Surgery in Women 70 Years of Age and Older: How Wisely Do We Choose? *Ann Surg Oncol*, 26(4), 969-975. doi:10.1245/s10434-018-07151-4
 96. Casuscelli, J., Becerra, M. F., Manley, B. J., **Zabor, E. C.**, Reznik, E., Redzematovic, A., Arcila, M. E., Tennenbaum, D. M., Ghanaat, M., Kashan, M., Stief, C. G., Carlo, M., Voss, M. H., Feldman, D. R., Motzer, R. J., Chen, Y., Reuter, V. E., Coleman, J. A., Russo, P., Hsieh, J. J., & Hakimi, A. A. (2019). Characterization and Impact of TERT Promoter Region Mutations on Clinical Outcome in Renal Cell Carcinoma. *Eur Urol Focus*, 5(4), 642-649. doi:10.1016/j.euf.2017.09.008
 97. Benefield, H. C., **Zabor, E. C.**, Shan, Y., Allott, E. H., Begg, C. B., & Troester, M. A. (2019). Evidence for Etiologic Subtypes of Breast Cancer in the Carolina Breast Cancer Study. *Cancer Epidemiol Biomarkers*

- Prev*, 28(11), 1784-1791. doi:10.1158/1055-9965.Epi-19-0365
98. Baker, J. L., Muhsen, S., **Zabor, E. C.**, Stempel, M., & Gemignani, M. L. (2019). Does Lymph Node Status Prior to Neoadjuvant Chemotherapy Influence the Number of Sentinel Nodes Removed? *Ann Surg Oncol*, 26(2), 336-342. doi:10.1245/s10434-018-7004-6
 99. Assel, M., Sjoberg, D., Elders, A., Wang, X., Huo, D., Botchway, A., Delfino, K., Fan, Y., Zhao, Z., Koyama, T., Hollenbeck, B., Qin, R., Zahnd, W., **Zabor, E. C.**, Kattan, M. W., & Vickers, A. J. (2019). Guidelines for Reporting of Statistics for Clinical Research in Urology. *J Urol*, 201(3), 595-604. doi:10.1097/ju.0000000000000001
 100. Assel, M., Sjoberg, D., Elders, A., Wang, X., Huo, D., Botchway, A., Delfino, K., Fan, Y., Zhao, Z., Koyama, T., Hollenbeck, B., Qin, R., Zahnd, W., **Zabor, E. C.**, Kattan, M. W., & Vickers, A. J. (2019). Guidelines for Reporting of Statistics for Clinical Research in Urology. *Eur Urol*, 75(3), 358-367. doi:10.1016/j.eururo.2018.12.014
 101. Assel, M., Sjoberg, D., Elders, A., Wang, X., Huo, D., Botchway, A., Delfino, K., Fan, Y., Zhao, Z., Koyama, T., Hollenbeck, B., Qin, R., Zahnd, W., **Zabor, E. C.**, Kattan, M. W., & Vickers, A. J. (2019). Guidelines for reporting of statistics for clinical research in urology. *BJU Int*, 123(3), 401-410. doi:10.1111/bju.14640
 102. **Zabor, E. C.**, Kaizer, A. M., & Hobbs, B. P. (2020). Randomized Controlled Trials. *Chest*, 158(1s), S79-s87. doi:10.1016/j.chest.2020.03.013
 103. Walsh, S. M., **Zabor, E. C.**, Flynn, J., Stempel, M., Morrow, M., & Gemignani, M. L. (2020). Breast cancer in young black women. *Br J Surg*, 107(6), 677-686. doi:10.1002/bjs.11401
 104. Vickers, A. J., Assel, M. J., Sjoberg, D. D., Qin, R., Zhao, Z., Koyama, T., Botchway, A., Wang, X., Huo, D., Kattan, M., **Zabor, E. C.**, & Harrell, F. (2020). Guidelines for Reporting of Figures and Tables for Clinical Research in Urology. *BJU Int*, 126(1), 14-25. doi:10.1111/bju.15102
 105. Vickers, A. J., Assel, M. J., Sjoberg, D. D., Qin, R., Zhao, Z., Koyama, T., Botchway, A., Wang, X., Huo, D., Kattan, M., **Zabor, E. C.**, & Harrell, F. (2020). Guidelines for Reporting of Figures and Tables for Clinical Research in Urology. *Eur Urol*, 78(1), 97-109. doi:10.1016/j.eururo.2020.04.048
 106. Vickers, A. J., Assel, M. J., Sjoberg, D. D., Qin, R., Zhao, Z., Koyama, T., Botchway, A., Wang, X., Huo, D., Kattan, M., **Zabor, E. C.**, & Harrell, F. (2020). Guidelines for Reporting of Figures and Tables for Clinical Research in Urology. *Urology*, 142, 1-13. doi:10.1016/j.urology.2020.05.002
 107. Vickers, A. J., Assel, M. J., Sjoberg, D. D., Qin, R., Zhao, Z., Koyama, T., Botchway, A., Wang, X., Huo, D., Kattan, M., **Zabor, E. C.**, & Harrell, F. (2020). Guidelines for Reporting of Figures and Tables for Clinical Research in Urology. *J Urol*, 204(1), 121-133. doi:10.1097/ju.0000000000001096
 108. Valero, M. G., Moo, T. A., Muhsen, S., **Zabor, E. C.**, Stempel, M., Pusic, A., Gemignani, M. L., Morrow, M., & Sacchini, V. (2020). Use of bilateral prophylactic nipple-sparing mastectomy in patients with high risk of breast cancer. *Br J Surg*, 107(10), 1307-1312. doi:10.1002/bjs.11616
 109. Valero, M. G., Muhsen, S., Moo, T. A., **Zabor, E. C.**, Stempel, M., Pusic, A., Gemignani, M. L., Morrow, M., & Sacchini, V. S. (2020). Increase in Utilization of Nipple-Sparing Mastectomy for Breast Cancer: Indications, Complications, and Oncologic Outcomes. *Ann Surg Oncol*, 27(2), 344-351. doi:10.1245/s10434-019-07948-x
 110. Valero, M. G., **Zabor, E. C.**, Park, A., Gilbert, E., Newman, A., King, T. A., & Pilewskie, M. L. (2020). The Tyrer-Cuzick Model Inaccurately Predicts Invasive Breast Cancer Risk in Women With LCIS. *Ann Surg Oncol*, 27(3), 736-740. doi:10.1245/s10434-019-07814-w
 111. Tadros, A. B., Moo, T. A., **Zabor, E. C.**, Gillespie, E. F., Khan, A., McCormick, B., Cahlon, O., Powell, S. N., Allen, R., Jr., Morrow, M., & Braunstein, L. Z. (2020). Feasibility of Breast-Conservation Therapy and Hypofractionated Radiation in the Setting of Prior Breast Augmentation. *Pract Radiat Oncol*, 10(5), e357-e362. doi:10.1016/j.prro.2020.01.003
 112. Tadros, A. B., Moo, T. A., Stempel, M., **Zabor, E. C.**, Khan, A. J., & Morrow, M. (2020). Axillary management for young women with breast cancer varies between patients electing breast-conservation therapy or mastectomy. *Breast Cancer Res Treat*, 180(1), 197-205. doi:10.1007/s10549-019-05520-5
 113. Raghunathan, N. J., **Zabor, E. C.**, Anderson, N., Oeffinger, K., Tonorezos, E. S., & Korenstein, D. (2020). Communicating cardiovascular risk to high-risk cancer survivors: a mixed-methods pilot study of a statin risk communication tool. *J Cancer Surviv*, 14(4), 417-423. doi:10.1007/s11764-020-00860-4
 114. Niehoff, N. M., **Zabor, E. C.**, Satagopan, J., Widell, A., O'Brien, T. R., Zhang, M., Rothman, N., Grimsrud, T. K., Van Den Eeden, S. K., & Engel, L. S. (2020). Prediagnostic serum polychlorinated biphenyl concentrations and primary liver cancer: A case-control study nested within two prospective cohorts. *Environ Res*, 187, 109690. doi:10.1016/j.envres.2020.109690

115. Minami, C. A., **Zabor, E. C.**, Gilbert, E., Newman, A., Park, A., Jochelson, M. S., King, T. A., & Pilewskie, M. L. (2020). Do Body Mass Index and Breast Density Impact Cancer Risk Among Women with Lobular Carcinoma In Situ? *Ann Surg Oncol*, 27(6), 1844-1851. doi:10.1245/s10434-019-08126-9
116. Iyer, G., Tully, C. M., **Zabor, E. C.**, Bochner, B. H., Dalbagni, G., Herr, H. W., Donat, S. M., Russo, P., Ostrovskaya, I., Regazzi, A. M., Milowsky, M. I., Rosenberg, J. E., & Bajorin, D. F. (2020). Neoadjuvant Gemcitabine-Cisplatin Plus Radical Cystectomy-Pelvic Lymph Node Dissection for Muscle-invasive Bladder Cancer: A 12-year Experience. *Clin Genitourin Cancer*, 18(5), 387-394. doi:10.1016/j.clgc.2020.02.014
117. Crown, A., Muhsen, S., **Zabor, E. C.**, Sevilimedu, V., Kelvin, J., Goldfarb, S. B., & Gemignani, M. L. (2020). Does Use of Neoadjuvant Chemotherapy Affect the Decision to Pursue Fertility Preservation Options in Young Women with Breast Cancer? *Ann Surg Oncol*, 27(12), 4740-4749. doi:10.1245/s10434-020-08883-y
118. Christian, N., **Zabor, E. C.**, Cassidy, M., Flynn, J., Morrow, M., & Gemignani, M. L. (2020). Contralateral Prophylactic Mastectomy Use After Neoadjuvant Chemotherapy. *Ann Surg Oncol*, 27(3), 743-749. doi:10.1245/s10434-019-08038-8
119. Brierley, C. K., **Zabor, E. C.**, Komrokji, R. S., DeZern, A. E., Roboz, G. J., Brunner, A. M., Stone, R. M., Sekeres, M. A., & Steensma, D. P. (2020). Low participation rates and disparities in participation in interventional clinical trials for myelodysplastic syndromes. *Cancer*, 126(21), 4735-4743. doi:10.1002/cncr.33105
120. Bilani, N., **Zabor, E. C.**, Elson, L., Elimimian, E. B., & Nahleh, Z. (2020). Breast Cancer in the United States: A Cross-Sectional Overview. *J Cancer Epidemiol*, 2020, 6387378. doi:10.1155/2020/6387378
121. **Zabor, E. C.**, Radivoyevitch, T., Singh, A. D., Kilic, E., de Klein, J., Kalirai, H., & Coupland, S. E. (2021). Conditional Survival in Uveal Melanoma. *Ophthalmol Retina*, 5(6), 536-542. doi:10.1016/j.oret.2020.09.015
122. **Zabor, E. C.**, Seshan, V. E., Wang, S., & Begg, C. B. (2021). Validity of a method for identifying disease subtypes that are etiologically heterogeneous. *Stat Methods Med Res*, 30(9), 2045-2056. doi:10.1177/09622802211032704
123. Tadros, A. B., Sevilimedu, V., Giri, D. D., **Zabor, E. C.**, Morrow, M., & Plitas, G. (2021). Survival Outcomes for Metaplastic Breast Cancer Differ by Histologic Subtype. *Ann Surg Oncol*, 28(8), 4245-4253. doi:10.1245/s10434-020-09430-5
124. Singh, A. D., **Zabor, E. C.**, & Radivoyevitch, T. (2021). Estimating Cured Fractions of Uveal Melanoma. *JAMA Ophthalmol*, 139(2), 174-181. doi:10.1001/jamaophthalmol.2020.5720
125. Raval, V., Luo, S., **Zabor, E. C.**, & Singh, A. D. (2021). Small Choroidal Melanoma: Correlation of Growth Rate with Pathology. *Ocul Oncol Pathol*, 7(6), 401-410. doi:10.1159/000517203
126. Radivoyevitch, T., **Zabor, E. C.**, & Singh, A. D. (2021). Uveal melanoma: Long-term survival. *PLoS One*, 16(5), e0250939. doi:10.1371/journal.pone.0250939
127. Pawloski, K. R., Tadros, A. B., Sevilimedu, V., Newman, A., Gentile, L., **Zabor, E. C.**, Morrow, M., Van Zee, K. J., & Kirstein, L. J. (2021). Patterns of invasive recurrence among patients originally treated for ductal carcinoma in situ by breast-conserving surgery versus mastectomy. *Breast Cancer Res Treat*, 186(3), 617-624. doi:10.1007/s10549-021-06129-3
128. Palacios, D. A., **Zabor, E. C.**, Munoz-Lopez, C., Roversi, G., Mahmood, F., Abramczyk, E., Kelly, M., Wilson, B., Abouassaly, R., & Campbell, S. C. (2021). Does Reduced Renal Function Predispose to Cancer-specific Mortality from Renal Cell Carcinoma? *Eur Urol*, 79(6), 774-780. doi:10.1016/j.eururo.2021.02.035
129. Luo, S., Raval, V., **Zabor, E. C.**, & Singh, A. D. (2021). Small Choroidal Melanoma: Correlation between Clinical Characteristics and Metastatic Potential. *Ocul Oncol Pathol*, 7(6), 437-446. doi:10.1159/000519672
130. Elimimian, E. B., Elson, L., Li, H., Liang, H., Bilani, N., **Zabor, E. C.**, Statler, A., & Nahleh, Z. (2021). Male Breast Cancer: A Comparative Analysis from the National Cancer Database. *World J Mens Health*, 39(3), 506-515. doi:10.5534/wjmh.200164
131. **Zabor, E. C.**, Reddy, C. A., Tendulkar, R. D., & Patil, S. (2022). Logistic Regression in Clinical Studies. *Int J Radiat Oncol Biol Phys*, 112(2), 271-277. doi:10.1016/j.ijrobp.2021.08.007
132. **Zabor, E. C.**, Raval, V., Luo, S., Pelayes, D. E., & Singh, A. D. (2022). A Prediction Model to Discriminate Small Choroidal Melanoma from Choroidal Nevus. *Ocul Oncol Pathol*, 8(1), 71-78. doi:10.1159/000521541
133. **Zabor, E. C.**, Kaizer, A. M., Garrett-Mayer, E., & Hobbs, B. P. (2022). Optimal Sequential Predictive

Probability Designs for Early-Phase Oncology Expansion Cohorts. *JCO Precis Oncol*, 6, e2100390. doi:10.1200/po.21.00390

134. **Zabor, E. C.**, Kane, M. J., Roychoudhury, S., Nie, L., & Hobbs, B. P. (2022). Bayesian basket trial design with false-discovery rate control. *Clin Trials*, 19(3), 297-306. doi:10.1177/17407745211073624
135. Sittenfeld, S., **Zabor, E. C.**, Hamilton, S. N., Kuerer, H. M., El-Tamer, M., Naoum, G. E., Truong, P. T., Nichol, A., Smith, B. D., Woodward, W. A., Moo, T. A., Powell, S. N., Shah, C. S., Taghian, A. G., Abu-Gheida, I., & Tendulkar, R. D. (2022). A multi-institutional prediction model to estimate the risk of recurrence and mortality after mastectomy for T1-2N1 breast cancer. *Cancer*, 10.1002/cncr.34352. Advance online publication. <https://doi.org/10.1002/cncr.34352>
136. Singh, A. D., Raval, V., Wrenn, J., & **Zabor, E. C.** (2022). Small Choroidal Melanoma: Outcomes After Surveillance Versus Immediate Treatment. *Am J Ophthalmol*, 241, 47-56. doi:10.1016/j.ajo.2022.03.024
137. Lemmon, C. A., **Zabor, E. C.**, & Pennell, N. A. (2022). Modeling the Cost-Effectiveness of Adjuvant Osimertinib for Patients with Resected EGFR-mutant Non-Small Cell Lung Cancer. *Oncologist*, 27(5), 407-413. doi:10.1093/oncolo/oyac021
138. Hobbs, B. P., Pestana, R. C., **Zabor, E. C.**, Kaizer, A. M., & Hong, D. S. (2022). Basket Trials: Review of Current Practice and Innovations for Future Trials. *J Clin Oncol*, Jco2102285. doi:10.1200/jco.21.02285
139. Eaton, A. A. *, & **Zabor, E. C.** * (2022). Analysis of composite endpoints with component-wise censoring in the presence of differential visit schedules. *Stat Med*. doi:10.1002/sim.9312
*equally contributing authors

Peer Reviewed Articles, Under Review

1. **Zabor, E. C.**, Kaizer, A. M., Pennell, N. A., & Hobbs, B. P. (Under review, *Frontiers in Oncology*). Optimal predictive probability designs for randomized biomarker-guided oncology trials.
2. **Zabor, E. C.**, Hobbs, B. P., Kane, M. J. (Under review, *R Journal*). ppsq: An R Package for Sequential Predictive Probability Monitoring.
3. Kaizer, A. M., **Zabor, E. C.**, Nie, L., & Hobbs, B. P. (Revise & resubmit, *PLOS ONE*). Bayesian and Frequentist Approaches to Sequential Monitoring for Futility in Oncology Basket Trials: A Comparison of Simon's Two-Stage Design and Bayesian Predictive Probability Monitoring with Information Sharing Across Baskets.
4. Javidi, H., Mariam, A., Khademi, G., **Zabor, E. C.**, Zhao, R., Radivoyevitch, T., & Rotroff, D. M. (Revise & resubmit, *Nature Digital Medicine*). Identification of Robust Deep Neural Network Models of Longitudinal Electronic Health Records.

Peer Reviewed Articles, Planned

1. **Zabor, E. C.**, & Eaton, A. A. (Work in progress, Planned submission July 2022, *Journal of the National Cancer Institute*). Using the estimand framework to address intercurrent events in oncology clinical trials: examples from disruptions due to the COVID-19 pandemic.

Invited, Non-Peer Reviewed

1. **Zabor, E. C.** (2018). ASO Author Reflections: Careful Development and Thoughtful Interpretation are Needed when Developing Online Prognostic Tools. *Ann Surg Oncol*, 25(Suppl 3), 916-917. doi:10.1245/s10434-018-6987-3
2. **Zabor, E. C.** (2021). Comment on "Age Conditional Probability of Ocular and Ocular Adnexal Malignancies". *Ocul Oncol Pathol*, 7(1), 74-75. doi:10.1159/000512031

Software / Application Development

1. **Zabor, E. C.** ezfun: R package to generate tables for clinical projects for use in word R Markdown files, <https://github.com/zabore/ezfun>. R package primarily intended for personal use.
2. **Zabor, E. C.** and Gönen, M. condsurv: R package for conditional survival analysis, <https://github.com/zabore/condsurv>. R package.
3. **Zabor, E. C.** riskclustr: Functions to Study Etiologic Heterogeneity. R package version 0.3. <https://cran.r-project.org/web/packages/riskclustr/>.
4. Sjoberg, D. D., Hannum, M., Whiting, K., & **Zabor, E. C.** (2020). gtsummary: Presentation-Ready Data Summary and Analytic Result Tables. R package version 1.3.4. <https://CRAN.R-project.org/package=gtsummary>.

5. **Zabor, E. C.**, Hobbs, B. P., & Kane, M. J. (2021). ppseq: Design Clinical Trials using Sequential Predictive Probability Monitoring. R package version 0.1.1. <https://cran.r-project.org/web/packages/ppseq/index.html>.

Letters

1. Moskowitz, C. S., **Zabor, E. C.**, & Jochelson, M. (2013). Response to the "letter to the editor" by Dr. Thomas Filleron. *Breast J*, *19*(2), 227. doi:10.1111/tbj.12094
2. Teo, M. Y., Bambury, R. M., **Zabor, E. C.**, Jordan, E., Al-Ahmadie, H., Boyd, M. E., Bouvier, N., Mullane, S. A., Cha, E. K., Roper, N., Ostrovnaya, I., Hyman, D. M., Bochner, B. H., Arcila, M. E., Solit, D. B., Berger, M. F., Bajorin, D. F., Bellmunt, J., Iyer, G., & Rosenberg, J. E. (2018). Commentary on "DNA damage response and repair gene alterations are associated with improved survival in patients with platinum-treated advanced urothelial carcinoma.". *Urol Oncol*, *36*(7), 345-346. doi:10.1016/j.urolonc.2018.05.011
3. Begg, C. B., Seshan, V. E., & **Zabor, E. C.** (2018). RE: "A MULTINOMIAL REGRESSION APPROACH TO MODEL OUTCOME HETEROGENEITY". *Am J Epidemiol*, *187*(5), 1129-1130. doi:10.1093/aje/kwy032
4. Moo, T. A., Edelweiss, M., Hajiyeva, S., Stempel, M., Raiss, M., **Zabor, E. C.**, Barrio, A. V., & Morrow, M. (2020). Correction to: Is Low-Volume Disease in the Sentinel Node After Neoadjuvant Chemotherapy an Indication for Axillary Dissection? *Ann Surg Oncol*, *27*(Suppl 3), 966. doi:10.1245/s10434-020-08273-4